CalciMedica is trading at $0.89 (6.2% up), extending a multi-day rebound following FDA alignment on the design and endpoints for its planned Phase 2b trial in acute pancreatitis.
- The stock previously jumped approximately 11% on July 29 following the news, as the company targets a disease category that currently has no approved therapies.
- Shares continue to attract speculative biotech interest despite broader sector weakness, suggesting the positive regulatory feedback remains the primary driver of investor sentiment.